158 related articles for article (PubMed ID: 16298156)
1. Treating the metabolic syndrome using angiotensin receptor antagonists that selectively modulate peroxisome proliferator-activated receptor-gamma.
Pershadsingh HA
Int J Biochem Cell Biol; 2006; 38(5-6):766-81. PubMed ID: 16298156
[TBL] [Abstract][Full Text] [Related]
2. Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property.
Yamagishi S; Takeuchi M
Med Hypotheses; 2005; 64(3):476-8. PubMed ID: 15617852
[TBL] [Abstract][Full Text] [Related]
3. Treating the metabolic syndrome: telmisartan as a peroxisome proliferator-activated receptor-gamma activator.
Kurtz TW
Acta Diabetol; 2005 Apr; 42 Suppl 1():S9-16. PubMed ID: 15868121
[TBL] [Abstract][Full Text] [Related]
4. [PPARgamma-activating properties of angiotensin receptor blockers].
Ando H; Fujimura A
Nihon Rinsho; 2006 Jul; 64 Suppl 5():498-501. PubMed ID: 16895217
[No Abstract] [Full Text] [Related]
5. New treatment strategies for patients with hypertension and insulin resistance.
Kurtz TW
Am J Med; 2006 May; 119(5 Suppl 1):S24-30. PubMed ID: 16563944
[TBL] [Abstract][Full Text] [Related]
6. The effects of irbesartan and telmisartan on metabolic parameters and blood pressure in obese, insulin resistant, hypertensive patients.
Negro R; Formoso G; Hassan H
J Endocrinol Invest; 2006 Dec; 29(11):957-61. PubMed ID: 17259791
[TBL] [Abstract][Full Text] [Related]
7. New approach in the treatment of T2DM and metabolic syndrome (focus on a novel insulin sensitizer).
Tjokroprawiro A
Acta Med Indones; 2006; 38(3):160-6. PubMed ID: 17119268
[TBL] [Abstract][Full Text] [Related]
8. Telmisartan and irbesartan therapy in type 2 diabetic patients treated with rosiglitazone: effects on insulin-resistance, leptin and tumor necrosis factor-alpha.
Derosa G; Cicero AF; D'Angelo A; Ragonesi PD; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo SA; Ferrari I; Gravina A; Fogari R
Hypertens Res; 2006 Nov; 29(11):849-56. PubMed ID: 17345784
[TBL] [Abstract][Full Text] [Related]
9. Effects of telmisartan and losartan on insulin resistance in hypertensive patients with metabolic syndrome.
Bahadir O; Uzunlulu M; Oguz A; Bahadir MA
Hypertens Res; 2007 Jan; 30(1):49-53. PubMed ID: 17460371
[TBL] [Abstract][Full Text] [Related]
10. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity.
Schupp M; Janke J; Clasen R; Unger T; Kintscher U
Circulation; 2004 May; 109(17):2054-7. PubMed ID: 15117841
[TBL] [Abstract][Full Text] [Related]
11. Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity.
Schupp M; Clemenz M; Gineste R; Witt H; Janke J; Helleboid S; Hennuyer N; Ruiz P; Unger T; Staels B; Kintscher U
Diabetes; 2005 Dec; 54(12):3442-52. PubMed ID: 16306360
[TBL] [Abstract][Full Text] [Related]
12. Telmisartan - killing two birds with one stone.
Doggrell SA
Expert Opin Pharmacother; 2004 Nov; 5(11):2397-400. PubMed ID: 15500387
[TBL] [Abstract][Full Text] [Related]
13. Telmisartan exerts renoprotective actions via peroxisome proliferator-activated receptor-γ/hepatocyte growth factor pathway independent of angiotensin II type 1 receptor blockade.
Kusunoki H; Taniyama Y; Azuma J; Iekushi K; Sanada F; Otsu R; Iwabayashi M; Okayama K; Rakugi H; Morishita R
Hypertension; 2012 Feb; 59(2):308-16. PubMed ID: 22252391
[TBL] [Abstract][Full Text] [Related]
14. Angiotensin type 1 receptor antagonists induce human in-vitro adipogenesis through peroxisome proliferator-activated receptor-gamma activation.
Janke J; Schupp M; Engeli S; Gorzelniak K; Boschmann M; Sauma L; Nystrom FH; Jordan J; Luft FC; Sharma AM
J Hypertens; 2006 Sep; 24(9):1809-16. PubMed ID: 16915030
[TBL] [Abstract][Full Text] [Related]
15. The differential effects of angiotensin II type 1 receptor blockers on microalbuminuria in relation to low-grade inflammation in metabolic hypertensive patients.
Yano Y; Hoshide S; Ishikawa J; Noguchi C; Tukui D; Takanori H; Tada M; Kanemaru Y; Yano A; Ishikawa S; Shimada K; Kario K
Am J Hypertens; 2007 May; 20(5):565-72. PubMed ID: 17485023
[TBL] [Abstract][Full Text] [Related]
16. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity.
Benson SC; Pershadsingh HA; Ho CI; Chittiboyina A; Desai P; Pravenec M; Qi N; Wang J; Avery MA; Kurtz TW
Hypertension; 2004 May; 43(5):993-1002. PubMed ID: 15007034
[TBL] [Abstract][Full Text] [Related]
17. PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin.
Clasen R; Schupp M; Foryst-Ludwig A; Sprang C; Clemenz M; Krikov M; Thöne-Reineke C; Unger T; Kintscher U
Hypertension; 2005 Jul; 46(1):137-43. PubMed ID: 15939809
[TBL] [Abstract][Full Text] [Related]
18. Effects of telmisartan on insulin resistance in Japanese type 2 diabetic patients.
Watanabe M; Inukai K; Sumita T; Ikebukuro K; Ito D; Kurihara S; Ono H; Awata T; Katayama S
Intern Med; 2010; 49(17):1843-7. PubMed ID: 20823643
[TBL] [Abstract][Full Text] [Related]
19. Partial peroxisome proliferator-activated receptor agonist angiotensin receptor blockers. Potential multipronged strategy in stroke prevention.
Towfighi A; Ovbiagele B
Cerebrovasc Dis; 2008; 26(2):106-12. PubMed ID: 18560212
[TBL] [Abstract][Full Text] [Related]
20. Role of insulin-sensitizing property of telmisartan, a commercially available angiotensin II type 1 receptor blocker in preventing the development of atrial fibrillation.
Yamagishi S; Takenaka K; Inoue H
Med Hypotheses; 2006; 66(1):118-20. PubMed ID: 16154710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
